Prognosis
FDA’s Hahn Vows to Stick to the Science Amid Vaccine Pressure
Commissioner Stephen Hahn spoke about not rubber-stamping a vaccine, trust in the agency, and dealing with politics
This article is for subscribers only.
The U.S. Food and Drug Administration is facing controversy after its commissioner, Stephen Hahn, substantially overstated the benefits of an experimental therapy for Covid-19 patients.
In a press conference with Trump, Hahn said the therapy — blood plasma from recovered patients — could save 35 of every 100 people who would have died. Those high-profile remarks were incorrect, and they were repeated by others in the Trump administration. Hahn late Monday clarified some of what the data on blood plasma actually show.